FEB 29, 2016 7:47 PM PST

How to make flu vaccine spray safe for little noses

Scientists have discovered a way to make a nasal spray flu vaccine safer for those who are at greatest risk of catching the flu, particularly infants under the age of 2.
 
"No one has tried to tweak a vaccine virus like this before," says Andrew Cox. "If we can make the nasal spray flu vaccine safer for very young children, it should provide better protection and remove a shot, which makes children and parents happy."

While the work is in very early stages and is a long way from being applied in people, it offers promise for a vaccine that could better protect the most vulnerable.

The currently available nasal spray vaccine, FluMist, is one of several types of flu vaccines offered every year, but it is only approved for use in people 2 through 49 years old. Infants, asthmatics, and older adults are not eligible for the vaccine, which is made from live flu virus that is dampened down so that it doesn’t cause the flu.

Because the virus is live, it activates multiple components of the immune system and creates a more robust immune response than the traditional shot version of the vaccine, which includes inactivated or killed flu virus.

Working with a vaccine similar to FluMist that is used in mice, researchers used molecular genetics to alter the vaccine virus so that it replicates only in the nose and not in the lungs. This is important because the main reason FluMist was not approved for use in children under the age of 2 is that it was associated with wheezing in infants in clinical trials.

A nasal spray flu vaccine is delivered via a spray into each nostril and moves from the nose through the respiratory tract to the lungs. If a vaccine virus enters the lungs it can create inflammation in response to the virus.

This presents a problem in very young children with narrow airways that are easily constricted. If the vaccine virus stays only in the nose, it eliminates the potential for wheezing, making it a safer option for infants, as well as individuals with asthma, says Andrew Cox, a graduate student in the laboratory of Stephen Dewhurst, vice dean for research and chair of the microbiology and immunology department at the University of Rochester.

“No one has tried to tweak a vaccine virus like this before,” says Cox, lead author of the study, which appears in the Journal of Virology. “If we can make the nasal spray flu vaccine safer for very young children, it should provide better protection and remove a shot, which makes children and parents happy.”

“FluMist is very safe in the populations that it is licensed for and creates a good immune response in kids ages 2 to 5, who are very susceptible to flu,” says John J. Treanor,  chief of the infectious diseases division at UR Medicine’s Strong Memorial Hospital. “It would be a major accomplishment if we were able to develop a live vaccine like FluMist for children ages 6 to 24 months.”

Many pediatricians stock the regular flu shot and not FluMist because the shot can be used for all ages. In most cases, if a parent wants FluMist, he or she has to ask for it, Cox says. “Not many doses of FluMist are given out, and that is a missed opportunity.”

“This puts us closer to having a safe and effective vaccine that can be used in people at greatest risk,” Dewhurst says.

Source: University of Rochester

This article was originally posted on futurity.org.
About the Author
  • Futurity features the latest discoveries by scientists at top research universities in the US, UK, Canada, Europe, Asia, and Australia. The nonprofit site, which launched in 2009, is supported solely by its university partners (listed below) in an effort to share research news directly with the public.
You May Also Like
MAR 03, 2020
Clinical & Molecular DX
MAR 03, 2020
Singapore charges ahead with antibody-based test for COVID-19
Researchers, biotech and pharmaceutical companies are scrambling to put an end to the coronavirus disease (COVID-19) out ...
MAR 28, 2020
Drug Discovery & Development
MAR 28, 2020
Could the Blood of Coronavirus Survivors Save Lives?
As the search for a treatment for coronavirus continues, a perhaps obscure-sounding candidate has begun to make headline ...
APR 20, 2020
Immunology
APR 20, 2020
Making Sense of the T Cell Response Spectrum
T cells go through a sort of “training” process throughout life, and scientists recently discovered that the ...
APR 20, 2020
Drug Discovery & Development
APR 20, 2020
First Successful Vaccine for Middle-East Respiratory Syndrome
Researchers have successfully completed the first-in-human clinical trial for a vaccine against MERS (Middle East Respir ...
MAY 19, 2020
Immunology
MAY 19, 2020
The Mystery of the Life-Saving Vaccine Solved
In the early 1900s, French bacteriologists Albert Calmette and Camille Guerin spent the better half of a decade developi ...
MAY 26, 2020
Immunology
MAY 26, 2020
The Hunt for Rare Immune Cells, to InfinityFlow and Beyond
The immune landscape is staggeringly complex, with a myriad of genetically and functionally distinct immune cell subpopu ...
Loading Comments...